Gamma Knife radiosurgery for vestibular schwannomas: evaluation of tumor control and its predictors in a large patient cohort in The Netherlands

Stijn Klijn, MD; Jeroen B. Verheul, MD, PhD; Guus N. Beute, MD; Sieger Leenstra, MD, PhD; Jef J. S. Mulder, MD, PhD; Henricus P. M. Kunst, MD, PhD; and Patrick E. J. Hanssens, MD

1Gamma Knife Center Tilburg, St. Elisabeth Hospital, Tilburg; 2Department of Neurosurgery, Erasmus Medical Center, Rotterdam; and 3Department of ENT, Radboud University Medical Center, Nijmegen, The Netherlands

OBJECTIVE The authors of this study sought to assess tumor control and complication rates in a large cohort of patients who underwent Gamma Knife radiosurgery (GKRS) for vestibular schwannoma (VS) and to identify predictors of tumor control.

METHODS The records of 420 patients treated with GKRS for VS with a median marginal dose of 11 Gy were retrospectively analyzed. Patients with neurofibromatosis Type 2 or who had undergone treatment for VS previously were excluded. The authors assessed tumor control and complication rates with chart review and used the Cox proportional hazards model to identify predictors of tumor control. Preservation of serviceable hearing, defined as Gardner-Robertson Class I–II, was evaluated in a subgroup of 71 patients with serviceable hearing at baseline and with available follow-up audiograms.

RESULTS The median VS tumor volume was 1.4 cm³, and the median length of follow-up was 5.1 years. Actuarial 5- and 10-year tumor control rates were 91.3% and 84.8%, respectively. Only tumor volume was a statistically significant predictor of tumor control rate. The tumor control rate decreased from 94.1% for tumors smaller than 0.5 cm³ to 80.7% for tumors larger than 6 cm³. Thirteen patients (3.1%) had new or increased permanent trigeminal nerve neuropathy, 4 (1.0%) had new or increased permanent facial weakness, and 5 (1.2%) exhibited new or increased hydrocephalus requiring a shunting procedure. Actuarial 3-year and 5-year hearing preservation rates were 65% and 42%, respectively.

CONCLUSIONS The 5-year actuarial tumor control rate of 91.3% in this cohort of patients with VS compared slightly unfavorably with the rates reported in other large studies, but the complication and hearing preservation rates in this study were similar to those reported previously. Various factors may contribute to the observed differences in reported outcomes. These factors include variations in treatment indication and in the definition of treatment failure, as well as a lack of standardization of terminology and of evaluation of complications. Last, differences in dosimetric variables may also be an explanatory factor.

http://thejns.org/doi/abs/10.3171/2015.4.JNS142415

KEY WORDS vestibular schwannoma; Gamma Knife radiosurgery; tumor control; complications; tumor volume; dosimetry; stereotactic radiosurgery

Abbreviations: CN = cranial nerve; GKRS = Gamma Knife radiosurgery; VS = vestibular schwannoma.


Include When Citing: Published online October 2, 2015; DOI: 10.3171/2015.4.JNS142415.
microsurgery is advised if the tumor is larger than 10 cm³. When serviceable hearing is present but declining, treatment is advised even in the absence of documented tumor growth. For larger tumors, however, a well-defined volumetric cut-off for the decision to treat with radiosurgery or microsurgery does not exist. Generally, VS tumors are accepted for radiosurgery if the tumor volume is below 10 cm³, unless symptoms of mass effect are present, and microsurgery is advised if the tumor is larger than 10 cm³. However, such large tumors are incidentally treated with radiosurgery when microsurgery is contraindicated because of comorbidities or high age, or when hearing preservation is of paramount importance. Until late 2010, we prescribed a dose of 11–13 Gy to the isodose covering 90% of the tumor volume, ensuring a marginal dose of approximately 11 Gy.

The purpose of this study was to assess tumor control and complication rates in our cohort of patients treated from 2002 to 2010 at our center and to compare the results obtained with those from other large cohorts reported in the literature. In addition, we sought to identify significant predictors of VS tumor control.

Methods

Patient Cohort

Between July 1, 2002, and November 1, 2010, we performed 604 consecutive GKRS procedures in patients with VS. The study cohort consisted of all VS patients remaining after excluding the following: patients with neurofibromatosis Type 2 (n = 33), those previously treated for VS (n = 139), and patients for whom follow-up data were unavailable (n = 12). In total, 420 patients who underwent GKRS as primary treatment for unilateral VS remained eligible, and their records were retrospectively analyzed.

The treatment indications in these patients were the following: evidence of radiological progression in 237 patients (56.4%), and in 114 patients (27.1%), the tumor was large at initial presentation (typically, when the tumor touched the brainstem), and a wait-and-scan approach was not considered appropriate. Thirty-seven patients (8.8%) with small but stable tumors were treated because they still had serviceable hearing, and we assumed that pro-active treatment would increase their chances of maintaining functional hearing. Ten patients (2.4%) preferred active treatment to a wait-and-scan strategy, even though treatment was not (yet) advised. In 22 patients (5.2%), the treatment indication was not specified.

Treatment and Follow-Up Protocols

For dose planning, T1-weighted MRI scans with and without Gd administration (0.1 mg/kg body weight) as well as T2-weighted MRI scans were obtained. The slice thickness was usually 1 or 2 mm with no slice gap. In 3 patients with contraindications for MRI, CT images were taken instead. The target volume was defined as the contrast-enhancing lesion. Until November 2008, 286 patients were treated with Leksell Gamma Knife 4C (Elekta AB); thereafter, 134 patients were treated with Leksell Gamma Knife Perfexion (Elekta AB).

Depending on tumor size and whether the patient still had serviceable hearing, a dose of 11–13 Gy was prescribed to the isodose covering 90% of the tumor volume, ensuring a marginal dose of approximately 11 Gy. In this study, the marginal dose is defined as the dose to 100% of the tumor volume. For the 4C model, dose calculations were performed with GammaPlan Wizard version 5.32 or Leksell GammaPlan 4C. For the Perfexion model, dose calculations were performed with Leksell GammaPlan version 8.3.1 or version 9.0.0. Follow-up imaging was performed within a standard interval of 1 year, which was often either shortened or extended according to current individual tumor size and control prognosis. Linear (2D) tumor size measurement was performed on the treatment and follow-up T1-weighted, Gd-enhanced MRI studies. In addition, for the purpose of this study, we measured volumetric (3D) tumor size. Tumors were defined as cystic if a significant spherical or oval-shaped mass was present that appeared hypointense on the T1-weighted images and hyperintense on the T2-weighted images. A neurosurgeon or radio-oncologist conducted a patient interview and neurological examination shortly before treatment and after every follow-up scan.

Collection of Study Data

All patient charts were reviewed to assess tumor control and complication rates. The tumor control rate was defined as 100% minus the fraction of cases in which treatment had failed. Treatment failure was defined as the requirement for additional treatment with either secondary GKRS, microsurgery, or a combination of the 2 procedures. We did not include shunting procedures for hydrocephalus in the definition of treatment failure.

The main indication for additional treatment was obvious tumor progression noted at consecutive measurements. We did not follow a uniform definition of progression, but we generally adhered to a minimum diameter increase of 2 mm in any direction as an indicator for progression. The final decision whether a patient required additional treatment was made in a multidisciplinary session involving at least a neurosurgeon, a radiation oncologist, and a radiologist. In all cases of radiological progression, a transient, radiation-induced swelling was taken into consideration and ruled out by evaluation of the tumor size on consecutive MRI scans.

Complications were defined as new or increased permanent CN symptoms (trigeminal numbness, paresthesia or pain/neuralgia; facial weakness reported as House-Brackmann grade; or tinnitus or vertigo) or hydrocephalus requiring a shunting procedure.

Audiograms before and after treatment were available for 71 patients who had serviceable hearing before the treatment. The audiograms were evaluated according to the Gardner-Robertson classification.6 Serviceable hearing was defined as Gardner-Robertson Class I–II (speech discrimination > 50% and pure tone average < 50 dB).

Statistical Analysis

Normal distribution of the data for each variable was vi-
sually inspected and tested with the Kolmogorov-Smirnov test. Data with a normal distribution are presented as mean ± SD, whereas data that were not normally distributed are presented as median and interquartile range. The product limit method of Kaplan and Meier was used to calculate actuarial tumor control and hearing preservation rates. Differences among strata were tested for statistical significance with the log-rank test. To test for possible predictors of tumor control, univariate and stepwise (forward conditional) multivariate analyses were performed using the Cox proportional hazards model. The following candidate predictor variables were tested: patient age, whether the tumor was cystic or not, tumor volume, and marginal radiation dose. A p value of < 0.05 was considered statistically significant.

**Literature Search**

Literature searches were performed on PubMed with the following query: (“neuroma, acoustic”[Mesh] OR vestibular schwannoma) AND (“radiosurgery”[Mesh] OR stereotactic OR Gamma Knife) AND (tumor control OR outcome OR results OR follow-up OR long-term OR complications OR dose). Search filters were set to English, “humans,” and publication date until March 1, 2015. The relevance of the articles retrieved was assessed by reading the titles, abstracts, or both. Articles were excluded if the study did not represent original research, the number of patients receiving GKRS as primary treatment for sporadic VS was < 100, dosimetry data (including marginal dose) was not available, data on tumor control at least 5 years posttreatment (actuarial or crude) was not available, or if we were unable to access the full text of the study. To minimize overlap in the patient cohorts presented, if several publications from the same authors or center were eligible for inclusion, we selected that study whose methods and design were most similar to ours (such as, for example, in the number of patients, follow-up length, etc.).

**Results**

**Descriptive Statistics**

The descriptive statistics of the characteristics of our patient cohort are presented in Table 1, and a summary of the GKRS dosimetry data used in this study is shown in Table 2. Data on symptoms arising from CN VIII (except hearing) before and after the treatment were available for 371 patients (88.3%).

**Tumor Control**

The GKRS treatment controlled the tumor in 375 patients (89.3%), and 45 patients (10.7%) required additional treatment (Fig. 1). Among the patients in the latter group, 32 (7.6%) received additional GKRS, and 13 (3.1%) required microsurgery. The actuarial 5- and 10-year tumor control rates were 91.3% and 84.8%, respectively. The median length of time between the first and the second treatment was 4.2 years (range 1.6–7.0 years) for patients requiring additional GKRS, and 3.1 years (range 0.3–5.1 years) for microsurgery. The indication for additional treatment was progression of the solid part of the tumor in 42 patients (10.0%), progression of the cystic part of the tumor in 2 patients (0.5%), and visual impairment and papilledema without radiological tumor progression in 1 patient (0.2%). In the 44 patients with tumor progression, 2 volumetric patterns were observed. Continuous growth was observed in 27 tumors; in these tumors, the mean volume increased from 2.91 to 6.67 cm³. Initial shrinkage or stabilization of the tumor followed by regrowth was observed in 17 tumors. In these tumors, the initial mean volume was 4.38 cm³, and the mean volume before retreatment was 4.03 cm³.

The potential predictors of VS tumor control are shown in Table 3. Only tumor volume statistically significantly predicted rates of tumor control (p < 0.01), and the tumor volume had a threshold effect (Table 3).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean patient age in yrs (range)</td>
<td>57.6 ± 12.7 (15–86)</td>
</tr>
<tr>
<td>M/F sex ratio (%)</td>
<td>218 (52):202 (48)</td>
</tr>
<tr>
<td>Tumor location (no. of pts [%])</td>
<td>Right 224 (53)</td>
</tr>
<tr>
<td></td>
<td>Left 196 (47)</td>
</tr>
<tr>
<td>Median tumor vol in cm³ (IQR [range])</td>
<td>1.4 (0.59–3.7 [0.01–17.7])</td>
</tr>
<tr>
<td>Cystic tumor (no. of pts [%])</td>
<td>Yes 30 (7)</td>
</tr>
<tr>
<td></td>
<td>No 390 (93)</td>
</tr>
<tr>
<td>Cystic part irradiated (no. of pts [%])</td>
<td>Yes 25 (53)</td>
</tr>
<tr>
<td></td>
<td>No 5 (17)</td>
</tr>
<tr>
<td>Median length of FU in yrs (IQR [range])</td>
<td>5.1 (4.0–7.0 [0.2–12.0])</td>
</tr>
<tr>
<td>Long-term FU (no. of pts [%])</td>
<td>≥2 yrs 405 (96)</td>
</tr>
<tr>
<td></td>
<td>≥4 yrs 330 (79)</td>
</tr>
<tr>
<td></td>
<td>≥6 yrs 169 (40)</td>
</tr>
<tr>
<td></td>
<td>≥8 yrs 68 (16)</td>
</tr>
<tr>
<td></td>
<td>≥10 yrs 22 (5)</td>
</tr>
<tr>
<td>Preexisting CN V neuropathy (no. of pts [%])</td>
<td>Trigeminal numbness &amp;/or paraesthesia 59 (14.0)</td>
</tr>
<tr>
<td></td>
<td>Trigeminal pain/neuralgia 6 (1.4)</td>
</tr>
<tr>
<td>Preexisting CN VII neuropathy (no. of pts [%])</td>
<td>Subjective facial weakness (not objectively assessed on physical exam) &amp;/or transient/intermittent facial spasm 10 (2.4)</td>
</tr>
<tr>
<td></td>
<td>Objectively assessed (on physical exam) facial weakness (HB Grade ≥II) 12 (2.9)</td>
</tr>
<tr>
<td>Preexisting CN VIII neuropathy (except hearing) (no. of pts [%])</td>
<td>Tinnitus 277 (75)</td>
</tr>
<tr>
<td></td>
<td>Vertigo 216 (58)</td>
</tr>
</tbody>
</table>

FU = follow-up; HB = House-Brackmann; IQR = interquartile range; pts = patients.

* Data represent the mean ± SD or median and IQR, depending on the normality of the data distribution.
control rates stratified by the volume of the tumor are shown in Fig. 2. The actuarial 5-year tumor control rate was statistically significantly higher in tumors < 0.5 cm³ (94.1%) than in tumors ≥ 0.5 cm³ (90.0%) (log-rank test, p < 0.05). In addition, the actuarial 5-year tumor control rate was statistically significantly higher in tumors < 6 cm³ (92.2%) than in tumors ≥ 6 cm³ (80.7%) (log-rank test, p < 0.05).

Complications
Thirteen of the patients (3.1%) had new or increased permanent trigeminal nerve neuropathy. Four patients (1.0%) had new or increased permanent facial weakness reported as a decrease in House-Brackmann grade (1 patient with Grade II, 2 with Grade IV, and 1 with Grade V). Five patients (1.2%) had new or increased hydrocephalus requiring a shunting procedure. In the 371 patients with available data on symptoms arising from CN VIII, new or increased symptoms of tinnitus were reported by 49 patients (13.2%), and new or increased symptoms of vertigo were noted by 55 patients (14.8%). The results for the rate of hearing preservation after GKRS among the 71 evaluable patients during the study period are shown in Fig. 3; in 43 of these patients (60.6%), serviceable hearing was preserved. The actuarial 3- and 5-year hearing preservation rates were 65% and 42%, respectively.

Literature Search
The query string described in Methods yielded 733 articles indexed in PubMed. After applying our exclusion criteria, 8 articles remained in our literature-based analysis. The tumor control and complication rates in these published cohorts are summarized in Table 4.

Discussion
The actuarial 5-year tumor control rate with GKRS in our study was 91.3%, which was lower than rates of 93%–97% tumor control reported by other large studies. However, 97% of our patients did not require microsurgery, which is well within the range of the 95%–99% rates observed in other studies. The CN complication and hearing preservation rates we observed here do not appear to be different from those reported in previous studies. In the following, we will discuss several possible explanations for these findings.

Selection of Patients
Opinions concerning if and when a patient with VS should undergo GKRS have changed over time. As the quality of planning improved, the treatment of larger tumors became more feasible. The decisions about the highest tumor volume that is considered eligible for GKRS may still differ among different centers. In the current study, we found that tumor volume is a statistically significant predictor of tumor control with GKRS, and this relationship was not confounded by the nature (cystic versus noncystic) of the tumor. Furthermore, centers treating only tumors that show radiological evidence of progression may obtain less favorable outcomes than centers that also treat stable tumors. However, previous results in a subgroup analysis of 100 patients suggest that documented tumor growth does not have an effect on tumor control.

Comparability of Studies
We note that many factors preclude a reliable comparison of our results with findings reported from other studies, and we discuss these factors in the following.

Actuarial Tumor Control Is Often Not Calculated
Some reports present only crude figures of tumor control, hampering a reliable comparison among studies.

Definitions of Treatment Failure and Complications Are Not Uniform Among Studies
In this study, treatment failure was defined as a requirement for additional treatment with secondary GKRS, microsurgery, or a combination of these procedures. Shunting procedures for hydrocephalus were not included in this definition and were instead considered a complication. Many other studies have provided different or unclear definitions of treatment failure and complications. Some studies define treatment failure as the requirement for microsurgical tumor resection and do not mention whether the need for a secondary GKRS is considered a treatment failure. Other studies have defined tumor control as the absence of radiologically identified progression. Two studies counted cases in which patients underwent shunting procedures for hydrocephalus as treatment failures.
To illustrate the importance of these differences in definition, we recalculated what our tumor control results would have been had we defined treatment failure as a 10% increase in tumor volume. In this scenario, the crude tumor control rate dropped from 89.3% to 77.8%. We also note that volumetric follow-up is much more sensitive for detecting tumor progression than 2D (linear) follow-up.27

We encountered similar problems with varying definitions among studies while attempting to compare our complication rate with those reported from other studies. For example, a diagnosis of CN complications depends on the subjective assessment of symptoms by both the patient and the clinician. Although the diagnosis of facial weakness is usually straightforward, objectively rating complications such as pain, vertigo, and tinnitus is more challenging. Moreover, there often is no consensus about which grading scale should be used, provided that one exists for a given symptom. Thus, uniformity in reporting these complications is lacking. Furthermore, it appears that hearing preservation after radiosurgery continues to decline.2 Studies on hearing preservation rates should therefore report actuarial instead of crude figures for serviceable hearing, especially in the long term.

The Requirement for Additional Treatment Is Not Based on Uniform Criteria

Although tumor progression is the indication for additional treatment in nearly all cases of VS, the decision if and when a clinician should proceed with additional treatment is inevitably a matter of judgment by different clinicians in different centers. Such decisions may depend on many patient-related and tumor-related variables such as patient age and comorbidities, the method of assessing tumor size (i.e., linear vs volumetric measurement), the magnitude of radiological progression that is considered significant and clinically relevant, and the time frame during which transient radiation-induced swelling is taken into consideration. Obviously, the relative importance of these and other variables is strongly influenced by tumor size. Although we attempted to describe our workup as clearly as possible, it is unlikely that clinicians from other centers would have made exactly the same decisions for all patients in our cohort.

The aforementioned issues illustrate the importance of guidelines and standardization of terminology in stereotactic radiosurgery as proposed by the Standardization Committee of the International Leksell Gamma Knife Society.26 Such standardization will also enable the com-

### TABLE 3. Candidate variables predicting tumor control

<table>
<thead>
<tr>
<th>Predictor</th>
<th>Hazard Ratio</th>
<th>p Value</th>
<th>Hazard Ratio*</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient age</td>
<td>0.99</td>
<td>0.31</td>
<td>—</td>
<td>0.48</td>
</tr>
<tr>
<td>Cystic/noncystic tumor</td>
<td>1.43</td>
<td>0.50</td>
<td>—</td>
<td>0.88</td>
</tr>
<tr>
<td>Tumor vol†</td>
<td>1.11</td>
<td>&lt;0.01</td>
<td>1.11</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Marginal dose</td>
<td>0.83</td>
<td>0.56</td>
<td>—</td>
<td>0.49</td>
</tr>
</tbody>
</table>

* The dashes in this column indicate that predictors did not statistically significantly add to the model in the multivariate analysis (i.e., their p values were > 0.05), and they were therefore excluded from the model.
† Both p values were statistically significant.

---

**FIG. 2.** Kaplan-Meier curves of actuarial tumor control rates, stratified by tumor volume. The continuous line indicates a tumor volume of < 0.50 cm³; long dashes depict a tumor volume of 0.50–1.99 cm³; short dashes correspond to a tumor volume of 2.00–5.99 cm³; and alternating long and short dashes indicate a tumor volume of ≥ 6 cm³.

**FIG. 3.** Kaplan-Meier curve of actuarial preservation of serviceable hearing (i.e., Gardner-Robertson Class I–II) among the patients of this study. Tick marks indicate censored cases.
comparison of outcomes after stereotactic radiosurgery with different treatment modalities. Another aspect that should be standardized is visualization and delineation of the target and relevant critical structures such as the cochlea. This project is currently underway within the International Leksell Gamma Knife Society.

Marginal Dose

Assuming that patient and tumor selection, definitions of outcome variables, and length of follow-up are perfectly comparable among the previous cohort studies and that our tumor control rate was therefore truly lower, a marginal dose of 11 Gy may be too low to achieve an optimal tradeoff between tumor control and complication rates. In the early years of GKRS, after many authors had observed that high marginal doses produce significant CN complications, the marginal dose was gradually decreased to reduce such complications. At present, most centers use marginal doses between 12 and 13 Gy without an apparent decline in tumor control.\(^1\) Since the first treatment at our center in 2002, we have prescribed a dose of 11–13 Gy to the isodose covering 90% of the tumor volume, ensuring a marginal dose of approximately 11 Gy. This strategy in dose prescription was adopted from experts in the field of GKRS.

In the entire cohort presented here, only 7 patients (1.7%) received a marginal dose of 12 Gy or higher. Considering our tumor control rate, when using marginal doses below 12 Gy, a turning point may have been reached when tumor control starts to decline while complication rates do not decrease any further. In 2011, we started to prescribe a dose of 11–13 Gy to the isodose covering 99% of the tumor volume, ensuring a marginal dose of approximately 11 Gy. This strategy in dose prescription was adopted from experts in the field of GKRS.

Study Limitations

The patients in this study were treated over a period of > 8 years, and indications for treatment may have changed during this time interval. During these 8 years, radiological evidence of progression has become more important in the decision to treat a VS. Furthermore, improved quality of planning and good treatment results have encouraged us now to accept tumors for GKRS that are larger than those considered for this treatment a decade ago. These changes may have influenced tumor control.

The retrospective nature of this study is a limitation. Although we are confident that important complications like facial weakness were thoroughly assessed and reported at each follow-up, it may be disputed whether measured symptoms such as, for example, tinnitus and vertigo, which are more difficult to objectively determine, can be accurately assessed on the basis of a chart review. In response to these concerns and for the purpose of future analysis, we currently use validated tinnitus and vertigo scores.\(^2\)
Hearing preservation is considered one of the most important issues in present VS management. The number of patients who had audiometric follow-up was limited in this study. This limitation is due to the nature of our institution as a tertiary referral center; audiograms are performed by the referring medical centers, not by our department. For the purpose of this study, we contacted referring centers to collect these audiometric data. The criteria for performing audiometric examinations may differ among these centers, but most conduct follow-up audiometry only if the patient reports decreased hearing. This may have biased the results of this study, leading to an underestimation of hearing preservation rates. Timmer et al. showed an important effect of the maximal cochlear dose on hearing preservation, which we had not yet recognized at the time of treatment of the patients in this study. We now aim to keep the cochlear dose below 4 Gy, and we expect that this lower cochlear dose will improve hearing preservation.

Conclusions

The actuarial 5-year tumor control of 91.3% in our cohort compared slightly unfavorably with those reported in other studies, but the complication and hearing preservation rates we observed here were comparable to previously observed rates. Various factors may contribute to the observed differences in some of the outcomes reported here. These factors include variations among studies in treatment indication and in the definition of treatment failure, as well as a lack of standardization of terminology and evaluation of complications. Last, differences in the dosimetric parameters may also explain some of the outcome differences. Standardization of terminology and in the assessment of complications may greatly increase the validity of future comparisons among large patient cohorts and may enable basing conclusions about outcome predictors on solid statistical procedures.

References

7. Hasegawa T, Kida Y, Kato T, Iizuka H, Kuramitsu S, Yamamoto T: Long-term safety and efficacy of stereotactic radio-


Disclosure
The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Author Contributions
Conception and design: Hanssens, Klijn, Verheul. Acquisition of data: Hanssens, Klijn, Verheul. Analysis and interpretation of data: Hanssens, Klijn, Verheul, Leenstra. Drafting the article: Klijn. Critically revising the article: all authors. Reviewed submitted version of manuscript: Hanssens, Klijn. Approved the final version of the manuscript on behalf of all authors: Hanssens. Statistical analysis: Klijn. Study supervision: Hanssens.

Supplemental Information
Previous Presentation
Portions of this work were presented as an oral presentation at the 10th Biennial Congress and Exhibition of the International Stereotactic Radiosurgery Society in Paris, France, May 8–12, 2011.

Correspondence
Patrick E. J. Hanssens, Gamma Knife Center Tilburg, St. Elisabeth Hospital, P.O. Box 90151, Tilburg 5000 LC, The Netherlands. email: p.hanssens@elisabeth.nl.